Management of 13 cases of canine respiratory disease using inhaled corticosteroids.
OBJECTIVE
To determine the value of inhaled corticosteroids in the management of chronic inflammatory airway disease in dogs.


METHODS
Medical records of dogs that were presented for the investigation of respiratory disease were reviewed retrospectively. Criteria for inclusion were knowledge of previous medical treatment including side effects, diagnosis of the underlying disease, use of inhaled corticosteroids and at least two-months follow-up data.


RESULTS
Thirteen dogs that fulfilled the criteria were identified. Ten dogs were diagnosed with chronic bronchitis and three with eosinophilic bronchopneumopathy. Four dogs had not previously received corticosteroid treatment for their respiratory disease, and all these showed a reduction or a resolution of clinical signs without obvious side effects after inhaled corticosteroid therapy. Nine dogs had previously received oral or parenteral corticosteroids for treatment of their respiratory disease, and all had exhibited side effects. Five of these dogs were treated with inhaled corticosteroids alone, and all exhibited an improvement in clinical signs without observable side effects. The remaining four dogs were treated with a combination of inhaled and oral corticosteroids, and all showed improvement in clinical signs and reduction in side effects. Inhaled medication was well tolerated in all dogs.


CONCLUSIONS
Inhaled corticosteroids were used for the management of chronic bronchitis and eosinophilic bronchopneumopathy in 13 dogs, and these may have the advantage of reducing side effects associated with oral corticosteroids.
Bexfield
N H
NH
Department of Veterinary Medicine, Queen's Veterinary School Hospital, University of Cambridge, UK.
Foale
R D
RD
Davison
L J
LJ
Watson
P J
PJ
Skelly
B J
BJ
Herrtage
M E
ME
D000280:Administration, Inhalation; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy / Q000662:veterinary; D001996:Bronchopneumonia / Q000188:drug therapy / Q000662:veterinary; D002908:Chronic Disease; D004283:Dog Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D005260:Female; D000068298:Fluticasone; D008297:Male; D011657:Pulmonary Eosinophilia / Q000188:drug therapy / Q000662:veterinary; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D000068298:Fluticasone; D001507:Beclomethasone